Related content

Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?

By Nguyen K.H.   Horwitz E.M.   Hanlon A.L.   Uzzo R.G.   Pollack A.  

International Journal of Radiation Oncology*Biology*Physics, Vol. 57, Iss. 2, 2003-10 ,pp. : 377-383

Elsevier

Access to resources Recommend Favorite

Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy

By Kalina Jennifer L.   Neilson David S.   Comber Alexandra P.   Rauw Jennifer M.   Alexander Abraham S.   Vergidis Joanna   Lum Julian J.  

Cancers, Vol. 9, Iss. 2, 2017-01 ,pp. : 13-13

MDPI

Access to resources Recommend Favorite

Intermittent Androgen Deprivation Therapy in Advanced Prostate Cancer

By Alva Ajjai   Hussain Maha  

Current Treatment Options in Oncology, Vol. 15, Iss. 1, 2014-03 ,pp. : 127-136

Springer Publishing Company

Access to resources Recommend Favorite

Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)

By Kitagawa Yasuhide   Ueno Satoru   Izumi Kouji   Mizokami Atsushi   Hinotsu Shiro   Akaza Hideyuki   Namiki Mikio  

Journal of Cancer Research and Clinical Oncology, Vol. 140, Iss. 4, 2014-04 ,pp. : 673-679

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)

By Cho D.   Di Blasio C.J.   Rhee A.C.   Kattan M.W.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 4, 2003-07 ,pp. : 282-291

Elsevier

Access to resources Recommend Favorite